Biopharma Summaries
Alhallak, Kinan ; Azab, Abdel Kareem
T-018892
— Disease indication – multiple myeloma Drug format – antibodies conjugated to nanoparticles for T-cell immunotherapy Drug class – improved delivery platform Research stage and Preliminary data: In vivo: In vitro proof of concept – in a MM cell line: NanoMuTEs and NanoTC…
TREM2 blockade as an adjuvant for checkpoint inhibitorsColonna, Marco
T-019371
— Disease indication – In combination with anti-PD-1 therapy for cancer. Anti-PD-1 therapy is currently approved for: Drug format – Monoclonal antibody Drug class – First-in-class Target – TREM2 Research stage and preliminary data – The inventors performed initia…
ELISpot assay to immune phenotype patientsHotchkiss, Richard ; Mazer, Monty ; Remy, Kenneth ; Turnbull, Isaiah
T-019522
— Technology Description A team of researchers, led by Richard Hotchkiss at Washington University in St. Louis, have developed a version of the ELISpot assay to determine if COVID-19 patients are in a hyper-inflammatory or immunosuppressed state. The results of this assay, which can be performed wit…
MRI and PET nanoparticle imaging agents for kidney disease diagnostics and transplant evaluationBaldelomar, Edwin ; Bennett, Kevin
T-019017
— Technology Description: Researchers at Washington University in St. Louis have developed targeted, natural nanoparticle imaging agents that may be used to quantify kidney nephron endowment and diagnose renal disease with MRI or PET imaging. Nephrons are the functional units of the kidney responsi…
Early, specific, blood-based diagnostic for septic arthritisLuhmann, Scott
T-018905
— Technology Description: Researchers at Washington University in St. Louis have identified blood-based cytokine signatures that could be used to specifically detect, distinguish and monitor septic arthritis, synovitis and osteomyelitis. This assay could enable timely, accurate treatment to avoid joi…
Engineered Oncolytic Zika Virus Therapy for GlioblastomaChheda, Milan ; Diamond, Michael ; Gorman, Matthew
T-017429
— T-017429 Engineered Oncolytic Zika Virus Therapy for Glioblastoma Technology Description Researchers in the laboratories of Michael Diamond and Milan Chheda at Washington University have developed prospective treatments for glioblastoma (GBM) through the application of an engineered Zika virus (ZI…
Uropathogen VaccinesDodson, Karen ; Ellebedy, Ali ; Feldman, Mario ; Hultgren, Scott ; Pinkner, Jerome ; Tamadonfar, Kevin ; Timm, Morgan
T-020120
— Technology Description Researchers in Scott Hultgren’s laboratory at Washington University have created two prospective vaccine treatments designed to prevent the colonization of prominent uropathogens. These vaccines have potential for treating urinary tract infections (UTIs) with specific m…
Treatments for multi-drug or broad addiction liabilityHatoum, Alexander
T-020521
— Technology Description Researchers at Washington University in St. Louis, led by Dr. Alexander Hatoum, have developed a computational model for improving the diagnosis and treatment of drug addiction. Using genome-wide association study (GWAS) of over 1 million subjects, Dr. Hatoum’s group d…
Antisense oligo to enhance neuronal survival in Huntington’s DiseaseOh, Youngmi ; Yoo, Andrew
T-020121
— Technology Description Researchers in Andrew Yoo’s laboratory at Washington University have developed an antisense oligonucleotide targeting a miRNA (miR-29b-3p) as a treatment for Huntington’s disease (HD). Inhibiting miR-29b-3p promotes neuronal survival by rescuing neurons from deg…
Combination therapy for malignant peripheral nerve sheath tumorsAmin, Neha ; Borcherding, Dana ; Hirbe, Angela
T-020000
— Technology Description Researchers in Angela Hirbe’s lab at Washington University have developed a method of treating malignant peripheral nerve sheath tumors (MPNSTs) with a combination of inhibitors. The most effective therapy is to combine an inhibitor of TYK2 with a MEK inhibitor. MPNST…
Technique to reduce juxta-anastomotic stenosis development in AV fistulaeShenoy, Surendra
T-010339
— Technology Description Researchers at Washington University in St. Louis have developed a technique for arteriovenous fistula creation that reduces the incidence of juxta-anastomotic stenosis, which often leads to graft failure. The procedure involves clamping closed one end of the graft and attac…
Oxygen-releasing hydrogel for rapid wound healingGuan, Jianjun ; Guan, Ya ; Niu, Hong
T-019931
— Technology Description Researchers in Jianjun Guan’s lab at Washington University have developed an oxygen-releasing hydrogel that accelerates wound healing. The biodegradable hydrogel is loaded with oxygen release microspheres (ORM) that slowly release oxygen into the surrounding tissue to …
Optimized MHC-independent T cell receptors as a CAR-T alternativeChang, Ju Fang ; Singh, Nathan
T-019636
— Technology Description Researchers in Nathan Singh’s lab at Washington University have developed a construct for cell therapy that combines facets of existing CAR-T therapy and the endogenous T cell receptor (TCR) to better regulate adoptive cell activation. Unlike the traditional TCR, this …
NRF2 inhibitors as cancer therapeuticsBowman, Brittany ; Dolle, Roland "Ron" ; Lapak, Kyle ; Major, Michael "Ben" ; Medcalf, Matthew
T-019534
— Disease indication – Diseases related to oxidative stress, including cancer, autoimmune disease, and Toxoplasma infection Drug format – Small molecule Drug class – Best-in-class Research stage and preliminary data – The researchers have synthesized a series of pyrimethamin…
Antibody blocking IL-12 and IL-23 receptors to treat inflammatory diseasesColonna, Marco ; Secca da Silva, Cristiane
T-019316
— Disease indication – Autoimmune diseases (plaque psoriasis, psoriatic arthritis, Crohn’s disease) Drug format – Monoclonal antibody Drug class – First-in-class Research stage and preliminary data – Researchers have stimulated human ILC3s with IL-23 in vitro, with and…
JAK inhibitor as conditioning agent for allogeneic hematopoietic stem cell transplantationDiPersio, John ; Persaud, Stephen "Steve"
T-019132
— Technology Description Researchers at Washington University in St. Louis have developed an improved process for conditioning patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) using JAK inhibitors. Commonly used to treat autoimmune diseases like rheumatoid arthritis, JAK inh…
Effective test for active tuberculosis infectionChandra, Pallavi ; Coullon, Heloise ; Philips, Jennifer
T-019244
— Technology Description Researchers in Jennifer Philips’ lab at Washington University in St. Louis have developed a more sensitive biomarker test for active tuberculosis infection. These biomarkers, found in the sputum and plasma, comprise of cholesterol metabolites that are cooperatively prod…
IP-10 as a blood biomarker of respiratory failureMudd, Philip
T-019671
— Technology Description Researchers in Philip Mudd’s lab at Washington University have developed a blood biomarker test that detects impending respiratory failure before existing diagnostics. High levels of the biomarker IP-10 in the blood are correlated with the subsequent development of acu…
Chimeric antigen receptor dendritic cellsDeSelm, Carl
T-019199
— Technology Description Researchers at Washington University in St. Louis have developed a genetic method to produce chimeric antigen receptor dendritic cells (CAR-DCs) for the treatment of solid tumors. The team generated a CAR that drives differentiation of cDC1s and mediates tumor-specific uptak…
Therapeutic targeting of LDL in ALSKreple, Collin ; Miller, Timothy ; Nielsen, Susan ; Racette, Brad
T-020021
— Technology Description Researchers in Brad Racette and Tim Miller’s labs at Washington University have developed a therapeutic strategy for treating ALS by using statins to lower LDL. Statins were successful at prolonging both survival and time with a normal gait. The researchers identif…
High-throughput blood biomarker test for peripheral atherosclerosisSemenkovich, Clay ; Zayed, Mohamed
T-017421
— Technology Description Researchers from Mohamed Zayed’s lab at Washington University have developed a blood biomarker test for atherosclerosis more accurate than LDL. Circulating levels of Fatty Acid Synthase (cFAS) in the serum correlate to a high degree to severity of peripheral atheroscle…
Mutant PDGF-B as a VEGFR inhibitorImoukhuede, Princess
T-018996
— Technology Description Researchers in the Imoukhuede lab at Washington University have developed a library of mutant PDGF-B proteins to develop more effective VEGF pathway inhibitors. As PDGF-B also binds to VEGF receptors, a mutant form can be used to block VEGF binding and stop tumor angiogenesi…
Targeting TPL2 in RAS-mutated cancersDodhiawala, Paarth ; Lim, Kian-Huat
T-019493
— Technology Description Researchers in Kian-Huat Lim’s lab at Washington University have developed a therapeutic strategy to target TPL2 in RAS-mutated cancers, which should work synergistically with chemotherapy and radiation. As TPL2 (MAP3K8) is necessary for upstream activation of both MAP…
Metabolic biomarkers for accurate, real-time diagnostics and monitoring of C. difficile infectionCrowley, Jan ; Henderson, Jeffrey P. ; Robinson, John
T-019079
— Technology Description Researchers in Prof. Jeffrey Henderson’s laboratory have developed a method of analyzing metabolic biomarkers from fecal samples to more accurately identify C. difficile infection (CDI) and distinguish between symptomatic and asymptomatic colonization. CDI is currently …
SARS-CoV-2 neutralizing antibodies with distinct epitopes effective against multiple variantsEllebedy, Ali
T-019707
— Disease indication – SARS-CoV-2 infection (COVID-19) Drug format Drug class – Best-in-class Research stage and Preliminary data – The inventors have developed and characterized these antibodies, creating a chimeric version with a human IgG backbone for SARS2-38. The antibodies have …
A novel modulator of tumor angiogenesis and anti-tumor immunityChoi, Kyunghee ; Kabir, Ashraf Ul ; Krchma, Karen
T-019294
— Technology Description Researchers in Kyunghee Choi’s lab at Washington University in St. Louis have identified a novel target, Myct1, that modulates tumor angiogenesis and anti-tumor immune response. Myct1 inhibition with siRNA blocks angiogenesis and promotes infiltration of cytotoxic T ly…
Anti-fungal treatment and companion diagnostic for Crohn’s DiseaseJain, Umang ; Stappenbeck, Thaddeus
T-019293
— Technology Description: Researchers at Washington University in St. Louis have identified a new avenue for treatment of non-healing ulcers in patients with Crohn’s disease by targeting Debaryomyces hansenii. While the cause of Crohn’s disease is unknown, the fungus D. hansenii colonize…
SARS-CoV-2 neutralizing antibody effective against all variantsAdams, Lucas ; Diamond, Michael ; Fremont, Daved ; VanBlargan, Laura
T-019791
— Disease indication – SARS-CoV-2 infection (COVID-19) Drug format – Chimeric monoclonal antibody Drug class – Best-in-class Research stage and Preliminary data – The inventors have developed and characterized this antibody, creating a chimeric version with a human IgG backbone. T…
Peptides responsible for Type 1 diabetesLichti, Cheryl ; Unanue, Emil ; Wan, Xiaoxiao
T-018626
— Technology Description: Researchers in the lab of Emil Unanue at Washington University have discovered a panel of peptides responsible for autoimmune activation in Type 1 diabetes and potentially capable of diagnosing T1D at an early stage. These peptide fragments of insulin are found circulating …
Predictive biomarker for CAR T-associated neurotoxicityAnces, Beau ; Butt, Omar ; DiPersio, John ; Ghobadi, Armin
T-019528
— Technology Description: Researchers at Washington University in St. Louis have developed a biomarker screening assay to predict which patients receiving CAR T cell therapy will experience neurotoxicity. Patients can be screened well in advance of receiving the T cell therapy with a simple serum as…
CCR2-targeted cancer nanoimmunotherapyLim, Kian-Huat ; Liu, Yongjian ; Zhang, Xiaohui
T-019463
— Disease indication – Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide Drug class – First-in-class Target – CCR2, the receptor for CCL2 Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…
TREM2 blockade as an adjuvant for checkpoint inhibitorsColonna, Marco
T-019371
— Disease indication – In combination with anti-PD-1 therapy for cancer. Anti-PD-1 therapy is currently approved for: Drug format – Monoclonal antibody Drug class – First-in-class Target – TREM2 Research stage and preliminary data – The inventors performed initia…
ELISpot assay to immune phenotype patientsHotchkiss, Richard ; Mazer, Monty ; Remy, Kenneth ; Turnbull, Isaiah
T-019522
— Technology Description A team of researchers, led by Richard Hotchkiss at Washington University in St. Louis, have developed a version of the ELISpot assay to determine if COVID-19 patients are in a hyper-inflammatory or immunosuppressed state. The results of this assay, which can be performed wit…
An alternative approach in antimalarial drug designDjuranovic, Sergej ; Erath, Jessey Lee ; Pavlovic Djuranovic, Slavica
T-018688
— Technology Description Researchers in Sergei Djuranovic’s lab at Washington University have developed polybasic peptides and polymers to block Plasmodium falciparum adhesion as a treatment for malaria. These therapeutics reduce parasite infection of human cells, making this a promising alter…
Method of increasing chemotherapy sensitivity in leukemia using BET inhibitorMitra, Robi ; Moudgil, Arnav ; Wilkinson, Michael Nathaniel
T-019486
— Technology Description Researchers in Robi Mitra’s lab at Washington University in St. Louis have developed a method to increase the sensitivity of leukemias to chemotherapy by pre-treatment with a BET inhibitor. BET inhibitors convert stem-like leukemia cells to a more differentiated state …
Fusion protein for treating multiple strains of Venezuelan equine encephalitis virusBasore, Katherine ; Diamond, Michael ; Fremont, Daved ; Kafai, Natasha ; Kim, Arthur ; Ma, Hongming ; Thackray, Larissa
T-019414
— Disease indication – Venezuelan equine encephalitis virus (VEEV) infection, either naturally-arising and as a result of bioterrorism Drug format – Biologic (soluble receptor fusion protein) Drug class – First-in-class Mode of action – This soluble fusion protein contains domain …
PI3K inhibitors to treat Cytokine Release SyndromeAmatya, Parmeshwar ; Carter, Alun ; Cooper, Matthew ; DiPersio, John
T-019429
— Technology Description A team of researchers, led by John DiPersio and Matthew Cooper at Washington University in St. Louis, have identified a small molecule kinase inhibitor capable of mitigating cytokine release syndrome following CAR-T cell therapy. PI3K inhibitors can suppress production of IL-…
An Intradermal Method for the Treatment of Hair Loss and AlopeciaFeng, Jing ; Hu, Hongzhen ; Luo, Jialie ; Yang, Pu
T-017716
— Technology Description: A team of researchers, led by Hongzhen Hu, at Washington University in St. Louis has developed a method of treating hair loss and alopecia by intradermal injection targeting TRPV4 activation. Using a small molecule TRPV4 agonist, a single intradermal injection is sufficient…
MRI and PET nanoparticle imaging agents for kidney disease diagnostics and transplant evaluationBaldelomar, Edwin ; Bennett, Kevin
T-019017
— Technology Description: Researchers at Washington University in St. Louis have developed targeted, natural nanoparticle imaging agents that may be used to quantify kidney nephron endowment and diagnose renal disease with MRI or PET imaging. Nephrons are the functional units of the kidney responsi…
Early, specific, blood-based diagnostic for septic arthritisLuhmann, Scott
T-018905
— Technology Description: Researchers at Washington University in St. Louis have identified blood-based cytokine signatures that could be used to specifically detect, distinguish and monitor septic arthritis, synovitis and osteomyelitis. This assay could enable timely, accurate treatment to avoid joi…
Interferon-gamma treatment to improve efficacy of hematopoietic stem cell transplantation for AML and other cancerChristopher, Matthew ; DiPersio, John ; Ley, Timothy ; Petti, Allegra ; Rettig, Michael
T-018954
— Technology Description Researchers at Washington University in St. Louis have discovered that interferon-gamma treatment could potentially prevent relapse after hematopoietic stem cell transplantation (HCT) treatment by making the cancer cells more visible to the donor immune cells. This technolog…
Fast, simple, low-cost point-of-care diagnostics for COVID-19 and other infectious diseasesBuchser, William ; Lalli, Matthew ; Milbrandt, Jeffrey ; Mitra, Robi
T-019442
— Technology Description A team of Washington University researchers has developed a low-cost molecular diagnostics kit and reader that could provide rapid, widespread screening and surveillance for SARS-CoV-2 and other infections. This technology utilizes a reverse-transcription loop-mediated isot…
Rapid Strep Throat Diagnostic Using Host Gene Expression AnalysisStorch, Gregory ; Yu, Jinsheng
T-019526
— Technology Description Researchers in Prof. Gregory Storch’s laboratory have developed a molecular assay that utilizes the patient/host gene expression pattern to rapidly identify acute group A streptococcus (GAS) infection in patients with pharyngitis (sore throat) to help guide appropriate…
Inflammatory bowel disease biomarkers and therapeutic targetKaiko, Gerard ; Liu, Ta-Chiang ; Stappenbeck, Thaddeus
T-017071
— Plasminogen activator inhibitor-1 (PAI-1) has been identified as a specific biomarker that is significantly elevated in patients with inflammatory bowel disease (IBD) and is correlated with disease severity. It could be used to both diagnose the disease (including ulcerative colitis and colonic Croh…
Nanomaterial to eliminate cold chain by preserving biological reagents and patient samplesKharasch, Evan ; Morrissey, Jeremiah ; Singamaneni, Srikanth ; Wang, Congzhou
T-017288
— Technology Description An interdisciplinary team at Washington University has developed low-cost, easy-to-use, nanoparticles that can preserve antibodies, proteins and other biological molecules without refrigeration. This technology employs metal organic frameworks (MOF) that can be used in two w…
Long non-coding RNA as cancer biomarker and drug targetCabanski, Christopher ; Fields, Ryan ; Maher, Christopher ; Silva-Fisher, Jessica
T-018788
— Technology Description Researchers in Prof. Christopher Maher’s research program (in conjunction with collaborator Ryan Fields) discovered that RAMS11 (RNA Associated with Metastasis 11), a novel long non-coding RNA, (i) promotes metastatic disease, (ii) confers resistance to topoisomerase i…
Treatment for chronic migrainesCao, Yu-Qing ; Cloud, Megan ; Hu, Rong ; Zhang, Jintao ; Zhang, Zhiyu
T-018942
— Technology Description Researchers at Washington University in St. Louis (WUSTL) have developed two methods for treating chronic migraine and post-traumatic headache. Chronic migraine and post-traumatic headache are highly prevalent and debilitating with limited treatment options. Further, for m…
Stimulating Innate Immune Cells for Cancer Therapy or Vaccine AdjuvantsBarrow, Alexander ; Colonna, Marco
T-016924
— Technology Description Researchers in Prof. Marco Colonna’s laboratory have identified a receptor-ligand interaction that could be harnessed to activate the innate immune system to treat cancer or enhance the response to vaccines for infectious disease. Specifically, platelet-derived growth f…
Method to generate functionally mature, stem-cell derived, beta cellsMillman, Jeffrey ; Velazco-Cruz, Leonardo
T-019270
— Technology Description Researchers at Washington University in St. Louis have developed an improved method to differentiate stem-cells into functionally mature, insulin-secreting beta cells (SC-beta cells). Pancreatic beta cells play an important role in controlling blood glucose levels as they se…
miRNA mimics to treat metabolic diseaseGong, Yong-feng ; Hou, Jianghui
T-017930
— Disease indication: metabolic disorders including insulin resistance and diabetic nephropathy Drug format: chemically modified synthetic microRNA (miRNA) Drug class: first-in-class for metabolic disease Research stage and Preliminary data: Target: miR-29 mimics can increase the gene expressio…
Prognostic for Lymphoproliferative DisordersQavi, Abraham ; Swat, Wojciech
T-019271
— Technology Description Researchers at Washington University in St. Louis have developed an improved method to monitor the progression of lymphoproliferative disorders (LPDs) and guide treatment decisions. LPDs, including leukemia and lymphoma, are characterized by the abnormal proliferation of blo…
Device for diabetes cell replacement therapyMillman, Jeffrey ; Song, Jiwon
T-016681
— Technology Description Researchers at Washington University in St. Louis have developed a 3D-printed device for the subcutaneous transplantation of stem cell-derived beta (SC-beta) cells for diabetes cell replacement therapy. Diabetes mellitus, a disease characterized by loss of blood glucose cont…
Targeted liposome drug delivery system to improve multiple myeloma treatmentAzab, Abdel Kareem ; Federico, Cinzia
T-019089
— Technology Description Researchers in Prof. Kareem Azab’s laboratory have developed a liposome drug delivery vehicle to improve efficacy and reduce side effects of multiple myeloma treatment. This system is designed to target compounds to the bone marrow microenvironment (BMME) and simultane…
Chimpanzee adenovirus-based vaccine for COVID-19Curiel, David ; Diamond, Michael ; Dmitriev, Igor ; Hassan, Ahmed
T-019478
— Technology Description Researchers at Washington University in St. Louis have developed a chimpanzee adenovirus-based vaccine for COVID-19. COVID-19, the clinical syndrome caused by SARS-CoV-2 infection, has had extensive morbidity and mortality impacts and destabilized society. There is an urg…
Eye test to diagnose preclinical Alzheimer’s diseaseApte, Rajendra ; Van Stavern, Gregory
T-018518
— Technology Description Researchers at Washington University in St. Louis have developed a non-invasive screening method using optical coherence tomography angiography (OCTA) to detect Alzheimer’s disease (AD) at the early, preclinical stage. AD is characterized by progressive memory loss, be…
Rapid PEG-based drug delivery implant for local treatment of cervical cancerAzab, Abdel Kareem ; Federico, Cinzia ; Schwarz, Julie ; Sun, Jennifer
T-019396
— Technology Description Researchers in Prof. Kareem Azab’s laboratory have developed a fast, localized drug delivery system designed to maximize anti-tumor efficacy and reduce side effects by delivering chemotherapy directly to cervical tumors. The current standard-of-care treatment regimen …
Recombinant VSV vector for COVID-19 vaccine or drug screeningRothlauf, Paul ; Whelan, Sean
T-019338
— Background: Recombinant vesicular stomatitis virus (VSV) has successfully been used to create a vaccine for Ebola virus that is currently on the market. Previously, Professor Sean Whelan and colleagues have exploited the VSV platform to create similar vectors for both SARS and MERS. Technology: The…
geOMV: Bacterial vaccine development platform using glycoengineered microbesFeldman, Mario
T-015094
— Technology Description Researchers in Prof. Mario Feldman’s laboratory have developed a patented, versatile, cost-effective platform for creating new multivalent vaccines for a variety of Gram-negative and Gram-positive bacteria. This technology, glycoengineered outer membrane vesicles (geOM…
Intestinal biomarker predicts response to treatment for inflammatory bowel diseaseStappenbeck, Thaddeus ; VanDussen, Kelli
T-019186
— Technology Description Researchers in the Stappenbeck lab have discovered an objective histologic biomarker on intestinal cells that can predict a patient’s response to ustekinumab treatment for Crohn’s disease or ulcerative colitis. Specifically, the length of microvilli (MV) could pr…
Nanomaterial to eliminate cold chain by preserving biological reagents and patient samplesKharasch, Evan ; Morrissey, Jeremiah ; Singamaneni, Srikanth ; Wang, Congzhou
T-016668
— Technology Description An interdisciplinary team at Washington University has developed low-cost, easy-to-use, nanoparticles that can preserve antibodies, proteins and other biological molecules without refrigeration. This technology employs metal organic frameworks (MOF) that can be used in two w…
Artificial antibody platform to eliminate cold-chain in label-free plasmonic biosensor detection for diagnostics and researchAbbas, Abdennour ; Kharasch, Evan ; Liu, Keng-Ku ; Morrissey, Jeremiah ; Singamaneni, Srikanth ; Tian, Limei
T-013772
— Technology Description An interdisciplinary team of researchers at Washington University have developed a patented plasmonic nanotransducer system with built-in, highly stable artificial antibodies that can quickly detect and quantify biological molecules. These artificial antibodies can be rapidl…
Liquid biopsy assay for personalized prostate cancer treatmentChaudhuri, Aadel ; Maher, Christopher ; Pachynski, Russell
T-019287
— Technology Description A team of researchers at Washington University has developed “EnhanceAR-Seq”, a circulating tumor DNA (ctDNA) assay that predicts which patients are at high risk for developing resistance to androgen receptor (AR)-directed treatment for metastatic prostate cancer…
Compound to treat alcohol use disorderCovey, Douglas ; Mennerick, Steven
T-019232
— Technology Description Researchers at Washington University in St. Louis have developed new compounds that may be used to treat alcohol use disorder (AUD). AUD, a common condition that takes a high personal and public health toll, is characterized by severe problems with drinking- sufferers may co…
Blood-based biomarkers of Alzheimer’s disease for diagnostics and clinical trialsCruchaga, Carlos ; Dube, Umber ; Ibanez, Laura
T-019198
— Technology Description: Researchers in Prof. Carlos Cruchaga’s laboratory have identified a sensitive and specific panel of circular RNAs (circRNA) that could be used for diagnosing, screening or monitoring patients with Alzheimer’s disease. The expression of these circRNAs tracks with …
Method to create designer stem cells for safer, more effective therapeuticsGuilak, Farshid
T-018758
— Technology Description Researchers at Washington University in St. Louis have developed a method to create designer stem cells which provide a safer, more effective cell therapy approach to treating disease. Cell-based regenerative therapies could potentially be used to treat many diseases and res…
Antibodies to transferrin receptorLadenson, Jack ; Porter, Sharon
T-000757
— Analyte: Transferrin Receptor (CD71) Antibody codes: 2B7.4 (4065) and 2F6.3 (4077) Publications:
Antibiotic-sparing small molecule therapy for urinary tract infection and other Gram-negative pathogensDodson, Karen ; Hultgren, Scott ; Omattage, Natalie ; Pinkner, Jerome ; Yuan, Peng
T-018046
— Technology Description Researchers in Prof. Scott Hultgren’s laboratory have discovered an antibiotic-sparing method for treating infections from E. coli and other Gram-negative bacteria. This approach is designed to block pathogens from colonizing their host by using small molecule inhibito…
Radium Chelation For Targeted Alpha Particle TherapyAbou, Diane ; Thorek, Daniel
T-019039
— Technology Description Researchers at Washington University in St. Louis have developed a method to chelate radium-223 and increase its utility in targeted alpha-particle therapy (TAT). TAT aims to deliver cytotoxic alpha-particles to cancer cells. Radium-223 is an alpha particle emitting isotope …
Synthetic Dendritic Cells for Expanding Antigen-Specific T Cells used in Cancer ImmunotherapyKlechevsky, Eynav ; Pathak, Amit ; Sarker, Bapi
T-017391
— Technology Description: A team led by Drs. Amit Pathak and Eynav Klechevsky have developed a soft alginate-gelatin matrix-based synthetic dendritic cell to rapidly expand and deliver CD8+ T cells for cancer immunotherapy. CD8+ T cells kill tumors, but current methods to expand them also activate r…
Use of ent-allopregnanolone to treat glaucomaCovey, Douglas ; Izumi, Yukitoshi ; Zorumski, Charles
T-018940
— Technology Description Researchers from Washington University in St. Louis and colleagues have identified ent-allopregnanolone (ent-AlloP) as a potential therapeutic to treat glaucoma. Glaucoma, the leading cause of irreversible blindness, results from damage to the retinal ganglion cells (RGSs) t…
Drug target and biomarker for multiple sclerosisKlein, Robyn ; Williams, Jessica
T-017623
— Technology Description Researchers in Prof. Robyn Klein’s laboratory have discovered that interferon lambda (IFN-λ) is a potential target for treating multiple sclerosis (MS), particularly secondary progressive MS (SPMS). Most patients with MS present with relapsing remitting MS (RRM…
Vaccine to prevent catheter-associated urinary tract infectionCaparon, Michael ; Flores-Mireles, Ana ; Hultgren, Scott ; Pinkner, Jerome
T-013965
— Technology Description Researchers at Washington University in St. Louis have developed a vaccine strategy to prevent catheter-associated urinary tract infections (CAUTIs). CAUTIs are the most common cause of hospital-acquired infections. Many of these are caused by Enterococcus bacteria. CAUTIs a…
Target and small molecule drugs to selectively neutralize bacteria in urinary tract infectionsHenderson, Jeffrey P.
T-018628
— Technology Description Researchers in Prof. Jeffrey Henderson’s laboratory have discovered a drug target and a class of small molecule candidates that could be used to selectively prevent pathogenic enterobacteria from causing diseases such as urinary tract infections (UTIs). Currently, UTI…
EMMI- non-invasive imaging method for safe, accurate, robust monitoring of uterine contractionsCahill, Alison ; Cuculich, Phillip ; Schwartz, Alan ; Wang, Yong
T-015805
— Technology Description Researchers at Washington University in St. Louis have developed an electromyometrial imaging (EMMI) method to non-invasively monitor uterine contractions. During pregnancy, many women experience preterm contractions. Sometimes these contractions progress to pre-term labor a…
Selective RANK ligand to treat osteoporosisFremont, Daved ; Nelson, Christopher ; Teitelbaum, Steven ; Warren, Julia
T-014404
— Disease indication – Osteoporosis, skeletal metastasis, and potentially rheumatoid arthritis, psoriasis, acute myeloid leukemia, and breast cancer Drug format – Engineered Protein Research stage and Preliminary data – Proof of concept in vitro and in vivo Target – Receptor A…
Exosome-based therapy for tendon injuries and other soft tissue repairShen, Hua
T-018565
— Technology Description: A team of researchers at Washington University has developed a cell-free, nano-sized extracellular vesicle (EV/exosome) system to enhance repair of soft musculoskeletal tissue. This technology leverages the natural anti-inflammatory effects of adipose-derived stem cells (ASC…
Cytokine therapy for juvenile dermatomyositis and other autoimmune diseasesAlinger, Joshua ; French, Anthony ; Throm, Allison
T-018911
— Technology Description Researchers in Prof. Anthony French’s laboratory have discovered a signaling mechanism associated with juvenile dermatomyositis (JDM) that could potentially be targeted with cytokine-based therapies to treat JDM as well as other autoimmune disorders. This therapeutic a…
Target and method to treat alphavirus infectionsBasore, Katherine ; Diamond, Michael ; Fremont, Daved ; Kim, Arthur ; Nelson, Christopher ; Thackray, Larissa ; Zhang, Rong
T-017583
— Technology Description Researchers at Washington University in St. Louis have identified a target for therapeutic development and created methods to potentially treat arthritogenic alphavirus infection. Arthritogenic alphaviruses, including chikungunya (CHIKV), Ross River, Mayaro and O’nyong…
NanoTCE: a nanoparticle antibody system for immunotherapy against heterogeneous multiple myelomaAlhallak, Kinan ; Azab, Abdel Kareem
T-018892
— Disease indication – multiple myeloma Drug format – antibodies conjugated to nanoparticles for T-cell immunotherapy Drug class – improved delivery platform Research stage and Preliminary data: In vivo: In vitro proof of concept – in a MM cell line: NanoMuTEs and NanoTC…
Ultrasound “painting” for precise, targeted drug delivery to the brainChen, Hong ; Williamson, Jeffrey ; Yang, Yaoheng "Mack"
T-018953
— Technology Description Researchers in Prof. Hong Chen’s laboratory have developed a safe, convenient monitoring technique to precisely deliver drugs to the brain by integrating ultrasound imaging with ultrasound therapy (focused ultrasound-blood-brain-barrier delivery, “FUS-BBBD”…
Alpha-synuclein ligands as specific PET imaging probes for Parkinson’s Disease and other disordersDhavale, Dhruva ; Kotzbauer, Paul ; Tu, Zhude "Will" ; Yue, Xuyi
T-018038
— Technology Description A team of researchers at Washington University have developed and optimized highly potent PET imaging probes which are specific for the misfolded protein that is the hallmark of Parkinson’s disease and related disorders. This family of molecules was designed based on s…
Potent, locally-acting chemokine binding proteins to protect organ transplants and treat ischemic or inflammatory diseasesFremont, Daved ; Lu, Yun Hsuan ; Lubman, Olga
T-017443
— Researchers in Prof. Daved Fremont’s laboratory have identified two potent, soluble proteins that could prevent damage to transplanted organs and potentially treat other autoimmune and inflammatory diseases by evading the immune response instigated by chemokines. In organ transplants, chemoki…
Therapy to treat and prevent respiratory disease in pre-term and at-risk neonatesMorley, Sharon "Celeste" ; Todd, Elizabeth (Betsy)
T-017434
— Technology Description Researchers in Prof. S. Celeste Morley’s laboratory have developed a long-lasting prophylactic therapy that could protect pre-term and at-risk infants from pneumonia, respiratory distress and bronchopulmonary dysplasia. Neonates born prematurely are at increased risk f…
Cell-based tumor targeting for delivering therapeutic and imaging agentsAzab, Abdel Kareem ; Muz, Barbara
T-018893
— Researchers in Prof. Abdel Kareem Azab’s laboratory have developed a biologically-targeted cellular drug delivery system to precisely target therapeutic or diagnostic agents to a wide range of cancers. Delivering drugs directly to cancer cells and not to healthy cells could improve outcomes by…
Simple, stable plasmonic biosensors for point-of-care diagnosis of cardiac arrest and other conditionsKharasch, Evan ; Morrissey, Jeremiah ; Singamaneni, Srikanth ; Tadepalli, Sirimuvva
T-014923
— Technology Description An interdisciplinary team of researchers at Washington University have developed a sensitive, shelf-stable, label-free system for quickly quantifying biomarkers in point-of-care settings (e.g., office, ambulance or battlefield). Localized surface plasmon resonance (LSPR) off…
MRI-based multiparametric cardiac strain analysis of myocardial viabilityCupps, Brian ; Pasque, Michael
T-006692
— Background: Assessing left ventricle (LV) cardiac contractile function is a good indicator of overall heart health and is used to determine which patients are good candidates for revascularization surgery. With over 3 million new coronary artery disease patients annually and over 1 million annual re…
Targeting hepatic arginine metabolism for treatment of metabolic diseasesDeBosch, Brian ; Higgins, Cassandra ; Mayer, Allyson ; Zhang, Yiming
T-017417
— Background Over 30% of adults in the world are overweight or obese. Lifestyle management has proven to be impractical and ineffective in real-life settings and there are no current treatments available for metabolic disease. Technology Summary Pharmacological or genetic activation of the Arginine…
Non-invasive Technology Enables Brain Tumor Biopsy Without SurgeryChen, Hong ; Dunn, Gavin ; Leuthardt, Eric ; Petti, Allegra
T-017113
— Background: The American Brain Tumor Association reports that about 80,000 of the estimated 700,000 Americans that live with a brain tumor have been diagnosed in 2017. The surgery required for a traditional brain tumor biopsy entails making a hole in the skin and skull, placing a needle probe, and r…
High Throughput Acoustic Particle SeparationBerezin, Mikhail ; Binkley, Michael ; Meacham, John
T-017364
— Technology Description: Methods and devices used for acoustophoresis of biologics have been developed and allow for more than 10,000 fold throughput than existing acoustophoretic devices. Applications: 1. Isolation of cells in low abundance (immune cells, circulating tumor cells) from whole bloo…
Drugs to supplement microglial metabolism during treatment of Alzheimer’s diseaseColonna, Marco ; Ulland, Tyler
T-017401
— Background: Alzheimer’s disease (AD) is the 6th leading cause of death in the United States, and yet causation of the disease is poorly understood and targets for therapeutic intervention are still being identified. Recently, mutations in the immune receptor TREM2 have been found to be strongl…
Sulfur-containing compounds targeting on vesicular acetylcholine transporter for cognitive functionJin, Hongjun ; Liu, Hui ; Luo, Zonghua ; Tu, Zhude "Will"
T-016517
— Background: Dementia caused by Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative diseases manifests as a progressive decline in memory and other cognitive abilities. Deposits of beta-amyloid plaques and tangles of the tau protein are thought to cause the destruction o…
Generating pancreatic beta cells from pluripotent stem cells for diabetes cell therapy or drug developmentHogrebe, Nathaniel ; Millman, Jeffrey ; Velazco-Cruz, Leonardo ; Veronese Paniagua, Daniel ; Wernes, Kristina
T-019409
— Technology Description: Researchers in Prof. Jeffrey Millman’s laboratory have developed multiple techniques for enhancing the differentiation, maturation and function of glucose-responsive, insulin-producing SC-beta cells (pancreatic beta cells made from human pluripotent stem cells). Downst…
Tissue engineering scaffold for cell differentiation and delivery to intervertebral disc for treating lower back painBarcellona, Marcos ; Setton, Lori ; Speer, Julie
T-019297
— Background: Severe low back pain and disability can result from intervertebral disc (IVD) degeneration caused by cell phenotype changes in the nucleus pulposus (NP) region. While autologous stem cells have be used to treat lower back pain, currently there are no tools to control differentiation of…
TR3: a stabilized TRAIL timer for use as an anticancer therapeuticHawkins, William ; Hotchkiss, Richard ; Spitzer, Dirk
T-007646
— WUSTL Technology 007646 Technology Description Researchers at Washington University in St. Louis (WUSTL) have developed a novel TRAIL (TNF-related apoptosis inducing ligand)-based anticancer drug platform, designated TR3. TRAIL has potent and specific apoptotic activity against tumor cells. Thus,…
Novel human astrovirus sequences for diagnostics and vaccine development for encephalitis and gastroenteritisFinkbeiner, Stacy ; Virgin, Herbert ; Wang, David ; Zhao, Guoyan
T-009294
— Technology Description A team of researchers at Washington University and the Centers for Disease Control discovered, sequenced and patented a novel human astrovirus that can cause encephalitis and gastroenteritis (non-etiologic diarrhea), offering a path to detection and diagnostics. The virus (…
A Truly Tumor-Specific Epitope Carried by BG-A Antigen for Cancer Diagnosis and TreatmentXu, Mai
T-016998
— Background: In the US alone, 154,000 new cases of colorectal cancer (CRC) are diagnosed each year. Unfortunately, a third of those patients will die due to diagnosis at late stages – the 5-year survival rate is 11%, compared to 91% for those who are diagnosed with only localized CRC. A colonos…
